Trastuzumab has been combined with cytotoxics, hormones, other monoclonal antibodies, such a pertuzumab and bevacizumab ... trastuzumab is the first monoclonal antibody to become available.

“We set out to make an antibody that can recognize a single ... There are a few FDA-approved therapies, including trastuzumab ...

The approval is based on findings from a phase 3 study which demonstrated the drug’s superiority over chemotherapy.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 ... with chemotherapy and an additional antibody therapy. Many people ask about alternative ...

blockade with trastuzumab and pertuzumab with the current standard of care, taxane plus trastuzumab and pertuzumab, in HER2-positive metastatic breast cancer (MBC). Compared with the taxane-based ...

Goa is making significant strides in healthcare with initiatives like the Cancer Screening Abhiyan, which has benefited ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

In breast cancer, to aim for curative therapy, blocking more than the pathway targeted by the monoclonal antibody, trastuzumab, will be required. Given the likelihood of cross-talk between the ...